PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression...
Main Authors: | Janzic Urska, Kern Izidor, Janzic Andrej, Cavka Luka, Cufer Tanja |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2017-09-01
|
Series: | Radiology and Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1515/raon-2017-0037 |
Similar Items
-
Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1
by: Liang Liu, et al.
Published: (2018-04-01) -
Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
by: Talip Zengin, et al.
Published: (2021-02-01) -
Schlafen 12 Is Prognostically Favorable and Reduces C-Myc and Proliferation in Lung Adenocarcinoma but Not in Lung Squamous Cell Carcinoma
by: Sarmad Al-Marsoummi, et al.
Published: (2020-09-01) -
Desmoglein 3 and Keratin 14 for Distinguishing Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
by: Dong Y, et al.
Published: (2020-10-01) -
Genomic profiles and transcriptomic microenvironments in 2 patients with synchronous lung adenocarcinoma and lung squamous cell carcinoma: a case report
by: Licheng Wu, et al.
Published: (2020-01-01)